AIFF (Firefly Neuroscience) EBIT per Share : $-0.65 (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Firefly Neuroscience EBIT per Share?

Firefly Neuroscience's EBIT per Share for the three months ended in Sep. 2024 was $-0.60. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.65.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Firefly Neuroscience's EBIT per Share or its related term are showing as below:

AIFF's 3-Year EBIT Growth Rate is not ranked ^*
in the Software industry.
Industry Median: 9.8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Firefly Neuroscience's EBIT for the three months ended in Sep. 2024 was $-4.27 Mil.

Firefly Neuroscience EBIT per Share Historical Data

The historical data trend for Firefly Neuroscience's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firefly Neuroscience EBIT per Share Chart

Firefly Neuroscience Annual Data

Trend

Dec21

Dec22

EBIT per Share

-0.54

-0.41

Firefly Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Jun23	Sep23	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial			-0.10	0.06	-0.08	-0.05	-0.60

Firefly Neuroscience EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Firefly Neuroscience's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.215	/	7.870
=	-0.41

Firefly Neuroscience's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.265	/	7.081
=	-0.60

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.65

Firefly Neuroscience (NAS:AIFF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Firefly Neuroscience EBIT per Share Related Terms

Thank you for viewing the detailed overview of Firefly Neuroscience's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Firefly Neuroscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Software » Firefly Neuroscience Inc (NAS:AIFF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 King Street W, 2nd Floor, Toronto, ON, CAN, M5H 1J9

Website

https://www.fireflyneuro.com

Firefly Neuroscience Inc is an AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support better outcomes for people suffering from mental illnesses and cognitive disorders.